Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.38 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.37 |
| ▸ | FDPS | P14324 | 5/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.35 |
| ▸ | LAP3 | P28838 | 1/20 | 0.34 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2960728 | 0.85 | TSHR (0.39) | TSHRPLA2G2CSMPD1FDPSALDH1A1 | |
| SCHEMBL18622176 | 0.83 | FDPS (0.42) | TSHRSMPD1FDPSLPAR3LAP3 | |
| SCHEMBL15302820 | 0.80 | SMPD1 (0.43) | SMPD1FDPSLPAR3LAP3LPAR2 | |
| SCHEMBL13239576 | 0.79 | TSHR (0.34) | TSHRPLA2G2CSMPD1FDPSLPAR3 | |
| SCHEMBL11215093 | 0.79 | SMPD1 (0.40) | SMPD1FDPSLPAR3LAP3LPAR2 | |
| SCHEMBL20365361 | 0.78 | CYP3A4 (0.42) | SMPD1FDPSLPAR3LAP3LPAR2 | |
| SCHEMBL27744277 | 0.78 | FDPS (0.41) | TSHRSMPD1FDPSLPAR3LAP3 | |
| SCHEMBL21377374 | 0.75 | CYP3A4 (0.38) | TSHRSMPD1FDPSLAP3 | |
| SCHEMBL2961043 | 0.75 | TSHR (0.42) | TSHRFDPSALDH1A1LPAR3LPAR2 | |
| SCHEMBL27984266 | 0.74 | LPAR3 (0.53) | SMPD1FDPSLPAR3LAP3LPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7754200-B2 | Phosphate transport inhibitors | GENZYME CORPORATION (US) | 2010-07-13 | — | — | US | disclosed |
| US-7754200-B2 | Phosphate transport inhibitors | GENZYME CORPORATION (US) | 2010-07-13 | — | — | US | disclosed |
| US-7754200-B2 | Phosphate transport inhibitors | GENZYME CORPORATION (US) | 2010-07-13 | — | — | US | disclosed |
| US-20060280719-A1 | Phosphate transport inhibitors | JOZEFIAK THOMAS H | 2006-12-14 | — | — | US | disclosed |
| US-7109184-B2 | Phosphate transport inhibitors | GENZYME CORPORATION (US) | 2006-09-19 | — | — | US | disclosed |
| EP-1485391-B1 | PHOSPHATE TRANSPORT INHIBITORS | GENZYME CORP (US) | 2006-08-23 | — | — | EP | disclosed |
| EP-1485391-A2 | PHOSPHATE TRANSPORT INHIBITORS | GENZYME CORPORATION (US) | 2004-12-15 | — | — | EP | disclosed |
| US-20040019020-A1 | Phosphate transport inhibitors | GELTEX PHARMACEUTICALS, INC. | 2004-01-29 | — | — | US | disclosed |
| WO-2003080630-A2 | PHOSPHATE TRANSPORT INHIBITORS | GENZYME CORPORATION (US) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060280719-A1 | Phosphate transport inhibitors | SLC34A2, SLC34A1, SLC43A1 | TSHR 76/4885PLA2G2C 3078/4885SMPD1 4350/4885 |
| US-20040019020-A1 | Phosphate transport inhibitors | SLC34A2, SLC43A1, SLC34A1 | TSHR 194/4885PLA2G2C 3216/4885SMPD1 4199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.